1. Yan, Hai, Parsons, D Williams, Jin, Genglin, Vogelstein, Bert, Bigner, Darell D. . IDH1 and IDH2 mutations in gliomas. In The New England journal of medicine, 360, 765-73. doi:10.1056/NEJMoa0808710. https://pubmed.ncbi.nlm.nih.gov/19228619/
2. Risueño, Alberto, See, Wendy L, Bluemmert, Iryna, Gandhi, Anita, Hasan, Maroof. 2024. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. In Leukemia research, 140, 107497. doi:10.1016/j.leukres.2024.107497. https://pubmed.ncbi.nlm.nih.gov/38564986/
3. DiNardo, C D, Tiong, I S, Quaglieri, A, Konopleva, M, Wei, A H. . Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. In Blood, 135, 791-803. doi:10.1182/blood.2019003988. https://pubmed.ncbi.nlm.nih.gov/31932844/
4. Figueroa, Maria E, Abdel-Wahab, Omar, Lu, Chao, Levine, Ross L, Melnick, Ari. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. In Cancer cell, 18, 553-67. doi:10.1016/j.ccr.2010.11.015. https://pubmed.ncbi.nlm.nih.gov/21130701/
5. Zhang, Ping, Zhang, Mingzhi. 2020. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. In Clinical epigenetics, 12, 169. doi:10.1186/s13148-020-00962-x. https://pubmed.ncbi.nlm.nih.gov/33160401/
6. Yoshimi, Akihide, Lin, Kuan-Ting, Wiseman, Daniel H, Krainer, Adrian R, Abdel-Wahab, Omar. 2019. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. In Nature, 574, 273-277. doi:10.1038/s41586-019-1618-0. https://pubmed.ncbi.nlm.nih.gov/31578525/
智鼠故事 
